HALO ▲ +1.2% - Halozyme Therapeutics, Inc. $HALO HALO - Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 Halozyme Therapeutics announced the pricing of a $1.3 billion private offering of convertible senior notes due 2033, prompting a 1.2% gain in the stock. The upsized offering suggests strong investor demand for the company's debt securities, which typically signals confidence in the company's financial position and future prospects. 17-SEP-2026 11:20 PM ET